enGene Therapeutics Inc. (NasdaqCM: ENGN)
Health Care · Biotechnology · CA
$1.88
+10.59% today · -53.8% 1Y
enGene Therapeutics Inc. (NasdaqCM: ENGN) operates in the Biotechnology industry within the Health Care sector. The company is valued at $113.88M and employs 82 people.
Over the last twelve months the share price has lost 53.8%, trading between 1.40 and 12.25.
Tweenvest scores enGene Therapeutics Inc. across four factors: quality 26/100. Its strongest factor is quality.
ENGN price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $113.88M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -2.12
- Dividend yield
- —
- Beta (5Y)
- -0.28
- 52-week high
- $12.25
- 52-week low
- $1.40
- Avg volume (3M)
- —
- Shares outstanding
- 66.99M
- Employees
- 82
- Next earnings
- —
About enGene Therapeutics Inc.
Operating through its subsidiary, enGene, Inc., enGene Holdings Inc. functions as a clinical-stage biotechnology firm. Its core mission involves pioneering genetic pharmaceuticals, achieved by administering therapeutic agents directly to mucosal tissues and other bodily organs. A key asset in its pipeline is EG-70, also known as detalimogene voraplasmid. This innovative non-viral immunotherapy is being developed to treat non-muscle invasive bladder cancer in patients diagnosed with carcinoma-in-situ (Cis) who have shown no improvement after Bacillus Calmette-Guérin therapy. The company was established in 2023 and is headquartered in Saint-Laurent, Canada.
- ISIN
- CA29286X1015
- Listed since
- Feb 1, 2022
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $266.00 | +0.08% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $442.45 | +0.05% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.74 | -0.02% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $552.00 | -0.15% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $832.63 | -0.11% |
| argenx SEENXTBR: ARGX | $64.17B | €909.60 | +3.46% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $157.49 | -0.84% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.